Coartem or Coarnate for uncomplicated malaria and parasite carriage in Rwanda

Submission date	Recruitment status	Prospectively registered
23/08/2010	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
25/10/2010	Completed	Results
Last Edited	Condition category	Individual participant data
25/10/2010	Infections and Infestations	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Stephen Rulisa

Contact details

Kigali University Teaching Hospital Department of Clinical research BP 655 Kigali Rwanda 655

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

No.187/RNEC/2010

Study information

Scientific Title

An open labeled randomised trial of Coartem vs. Co-Arinate for uncomplicated malaria and parasite carriage in Rwanda

Acronym

CoCo Trial

Study objectives

Coarinate is as effective as coartem

Ethics approval required

Old ethics approval format

Ethics approval(s)

The Rwanda National Ethics Committee approved on the 31st of March 2010 (ref: No.187 /RNEC / 2010)

Study design

Open label randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Prevention

Participant information sheet

Not available in web format, please use contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Malaria

Interventions

Patients will be randomised to receive

- 1. Coartem (arthemeter lumifantrine)
- 5-14 kg 20 mg arthemeter+120 mg lumefantrine 2/day for 3 days
- 15-24 kg: 40 mg arthemeter+ 240 mg lumefantrine 2/day for 3 days
- 25-34 kg: 60 mg arthemeter+360 mg lumefantrine 2/day for 3 days
- 34+ kg: 80 mg arthemeter + 480 mg lumefantirne 2/day for 3 days
- 2. Co-arinate (artesunate + sulfamethoxypyrazine + pyrimethamine)
- 5-14 kg: 50 mg artesunate+125mg sulfamethoxypyrazine+6.25mg pyrimethamine (t=0 and 12 and 24 hrs later)

15-25 kg: 100 mg artesunate+250mg sulfamethoxypyrazine+12.5 mg pyrimethamine (t=0 and 12 and 24 hrs later)

25-34 kg: 150 mg artesunate+ 375 mg sulfamethoxypyrazine+ 18.75 mg pyrimethamine (t=0 and 12 and 24 hrs later)

35+ kg: 200 mg artesunate+500 mg sulfamethoxypyrazine+25 mg pyrimethamine (t=0 and 12 and 24 hrs later)

All drugs will be given orally. Follow-up of all participants will be at day 0, day 1, day 7, day 14, day 21, day 28, day 35 and day 42.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Coartem, coarnate

Primary outcome measure

Parasite clearance as per WHO guidelines:

Full parasitological an clinical responses after 42 days of follow-up as measured by microscopy examination. At every follow-up visit a microscopy slide will be examined for parasites and counted against 200 whole blood count (WBC).

Secondary outcome measures

Gametocyte carriage:

At day 0,day 1, day 7 and day 14 blood samples (50 ul on filter paper) will be collected for molecular analysis of gametocytes. After nucleic acid extraction analysis will be done with NASBA and results will be expressed as gametocytes/ul

Overall study start date

15/09/2010

Completion date

30/06/2011

Eligibility

Key inclusion criteria

- 1. Either sex, age > 6 months
- 2. Simple malaria

Participant type(s)

Patient

Age group

Child

Lower age limit

6 Months

Sex

Not Specified

Target number of participants

900

Key exclusion criteria

Severe malaria

Date of first enrolment

15/09/2010

Date of final enrolment

30/06/2011

Locations

Countries of recruitment

Rwanda

Study participating centre Kigali University Teaching Hospital

Kigali Kigali Rwanda 655

Sponsor information

Organisation

INTERACT - Centre for Poverty related Communicable Diseases (CPCD) (Rwanda)

Sponsor details

Boulevard de la revolution Kigali Rwanda 00

Sponsor type

Not defined

Funder(s)

Funder type

Research organisation

Funder Name

INTERACT (Rwanda)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration